On July 2, Alnylam Pharmaceuticals rose 5.01% in regular trading, trading at $317.17/share, with turnover of $69.34 million.

The rally was fueled by a series of recent strategic partnership announcements and broader biotech sector strength. Most recently, the company expanded its strategic partnership with Komodo Health to deploy the Marmot AI analytics platform across its customer-facing and broader enterprise functions. Earlier, Alnylam announced a collaboration with Inceptive valued at up to $2 billion, including $30 million upfront, to leverage AI in accelerating RNAi therapeutic discovery. The company also expanded its commercial partnership with Genesis Pharma into four Nordic markets for its RNA interference therapeutics portfolio.

Fundamentally, Alnylam reported strong Q1 results with adjusted EPS of $1.99 versus $1.41 expected, and revenue of $1.17 billion, while reiterating full-year product revenue guidance of $4.90-$5.30 billion. Within the Biotechnology sector, the overall trend was positive, with Moderna up 7.05%, Abivax up 9.45%, Vertex Pharmaceuticals up 4.88%, and Gilead Sciences up 4.06%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)